Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Hum Genet ; 25(7): 886-888, 2017 06.
Article in English | MEDLINE | ID: mdl-28443623

ABSTRACT

In a 51-year-old patient of consanguineous parents with a severe neuromuscular phenotype of early-onset ataxia, myoclonia, dysarthria, muscle weakness and exercise intolerance, exome sequencing revealed a novel homozygous variant (c.-264_31delinsCTCACAAATGCTCA) in the mitochondrial FAD-transporter gene SLC25A32. Flavin adenine dinucleotide (FAD) is an essential co-factor for many mitochondrial enzymes and impaired mitochondrial FAD-transport was supported by a reduced oxidative phosphorylation complex II activity in the patient's muscle, decreased ATP production in fibroblasts, and a deficiency of mitochondrial FAD-dependent enzymes. Clinically, the patient showed improvement upon riboflavin treatment, which is a precursor of FAD. Our results confirm the recently reported case of SLC25A32 as a cause of riboflavin-responsive disease. Our patient showed a more severe clinical phenotype compared with the reported patient, corresponding with the (most likely) complete absence of the SLC25A32-encoding MFT (Mitochondrial Folate Transporter) protein.


Subject(s)
Ataxia/genetics , Dysarthria/genetics , INDEL Mutation , Membrane Transport Proteins/genetics , Muscle Weakness/genetics , Ataxia/diagnosis , Ataxia/drug therapy , Cells, Cultured , Dysarthria/diagnosis , Dysarthria/drug therapy , Fibroblasts/metabolism , Humans , Male , Middle Aged , Muscle Weakness/diagnosis , Muscle Weakness/drug therapy , Phenotype , Riboflavin/metabolism , Riboflavin/therapeutic use , Syndrome , Vitamin B Complex/metabolism , Vitamin B Complex/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...